Opendata, web and dolomites

ClearRing SIGNED

An innovative, minimally invasive medical device used for treatment of Benign Prostatic Hyperplasia symptoms

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

 ClearRing project word cloud

Explore the words cloud of the ClearRing project. It provides you a very rough idea of what is the project "ClearRing" about.

safe    causing    authorisation    rapid    men    implantable    clinical    validation    comparatively    risk    waiting    reimbursement    prostatic    therapy    validate    urinary    carry    urological    function    standard    twice    whereas    revolutionary    solution    drugs    ce    inside    reduces    quality    hospitals    bothersome    procedure    puts    resume    preservers    patient    urethra    mark    migration    200    efficacy    lifestyles    operation    affordable    randomized    symptoms    fast    presses    bph    medical    benign    introduce    position    complications    minimally    90    60s    blocks    obtain    clearring    safety    surgery    70       trial    severity    patients    implant    gradually    shaped    centres    diseases    costly    worsening    first    health    potentially    age    watchful    enlarges    unmet    life    invasive    significantly    seek    normal    efficient    prostate    proarc    company    worldwide    sexual    undesirable    instead    million    enlargement    chance    encrustation    treatment    hyperplasia    tolerable    alternative   

Project "ClearRing" data sheet

The following table provides information about the project.

Coordinator
PROARC MEDICAL LTD 

Organization address
address: KIDMA 23
city: PARDES HANA
postcode: 3707923
website: n.a.

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Israel [IL]
 Total cost 2˙776˙750 €
 EC max contribution 1˙943˙725 € (70%)
 Programme 1. H2020-EU.3. (PRIORITY 'Societal challenges)
2. H2020-EU.2.3. (INDUSTRIAL LEADERSHIP - Innovation In SMEs)
3. H2020-EU.2.1. (INDUSTRIAL LEADERSHIP - Leadership in enabling and industrial technologies)
 Code Call H2020-SMEInst-2018-2020-2
 Funding Scheme SME-2
 Starting year 2019
 Duration (year-month-day) from 2019-08-01   to  2021-07-31

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    PROARC MEDICAL LTD IL (PARDES HANA) coordinator 1˙943˙725.00

Map

 Project objective

Benign Prostatic Hyperplasia (BPH), or prostate enlargement, is one of the most common urological diseases among men. As the prostate enlarges with the age, it presses on and blocks the urethra, causing bothersome urinary symptoms. Over 70% of men in their 60s have symptoms of BPH 1, and 80-90% of men over 80 year old. BPH affects around 200 million men worldwide. The current methods present a significant unmet need for minimally invasive or less invasive BPH therapy as a less costly, more tolerable, and comparatively safe alternative to drugs and invasive surgery, which carry greater risk of undesirable side effects and complications. ClearRing is a revolutionary treatment of BPH symptoms, based on a pre-shaped implant and a dedicated delivery system. The ClearRing solution is the only minimally invasive system for BPH which is implantable inside the prostate with 0% chance of migration or encrustation. It puts ProArc in a unique position as a first company providing significantly improved health conditions and quality of life. Its rapid procedure enables hospitals to get patients in and out more quickly, creating a better patient experience as well as a more efficient management of medical resources. The minimally invasive procedure reduces the range and severity of side effects allowing patients to resume their normal lifestyles potentially twice as fast as the current standard operation procedure. Furthermore, it preservers sexual function. Overall objective of ProArc is to introduce a BPH treatment which is effective, affordable and with no side-effects, therefore men seek for the treatment instead of watchful waiting for the worsening. Whereas, the key objective of the project is to validate the ClearRing safety and efficacy for BPH treatment through a randomized clinical trial at 3 medical centres. This large scale clinical validation will enable ProArc to obtain the CE mark, and gradually apply for the reimbursement authorisation.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "CLEARRING" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "CLEARRING" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.3.;H2020-EU.2.3.;H2020-EU.2.1.)

DeltaQon (2019)

IOT and cloud computing for online medical analysis service platform

Read More  

Colourganisms (2020)

Microbial production of custom-made, pure and sustainable anthocyanins

Read More  

CAARESYS (2019)

CAARESYS: vehicle passenger monitoring system based on contactless low emission radio frequency radar.

Read More